Drugs / KFA115
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05544929 | Oct 2022 → Sep 2027 expected | anus cancer, cutaneous melanoma, gastroesophageal cancer, head and neck squamous cell carcinoma +7 | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KFA115 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05544929 ↗ |